Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
1. Pivot, X et al. Patient preference for subcutaneous versus intravenous trastuzumab: Results of the PrefHer study presented at St Gallen (March 2013)
2. Samanta, K et al. The study, Cost Savings with Herceptin subcutaneous vs intravenous administration: A time in motion study. Roche Products Ltd. Presented at St Gallen (March 2013)
3. Rarer Cancers Forum (2008), Exceptional England? An investigation of the role of Primary Care Trusts in making cancer medicines available through exceptional cases processes
4. Mistry, M. Cancer incidence in the United Kingdom: projections to the year 2030, British Journal of Cancer (2011) 105, 1795-1803
5. NHS Choices. About the NHS. Available here. Pages/overview.aspx Last accessed March 2013
6. Department of Health. NHS Operating Framework for the NHS in England 2011-2012.Available here (PDF) Last accessed March 2013
7. Macmillan - Cancer Information – Hormone and HER2 receptors Last accessed February 2013
8. Macmillan - About Breast Cancer Last Accessed February 2013
9. Boekhout, A.H. et al. (2011) Clinical Pharmacology: Concise Drug Reviews. Trastuzumab. The Oncologist; 16: 800-810
10. Rugo H et al. (2010) Effect of Trastuzumab on Health - Related Quality of Life in Patients With HER2-Positive Metastatic Breast Cancer: Data From Three Clinical Trials. Clin Breast Cancer 1;10(4):288-9
11. Herceptin® SmPC Roche Products Ltd. Herceptin® SmPC. January 2013 available here
Source: Roche in the UK
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Breast Cancer category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Roche. "HER2-Positive Breast Cancer Patients Prefer Faster Subcutaneous Administration Of Herceptin® (Trastuzumab) To IV." Medical News Today. MediLexicon, Intl., 19 Mar. 2013. Web.
18 Apr. 2014. <http://www.medicalnewstoday.com/releases/257799>
Roche. (2013, March 19). "HER2-Positive Breast Cancer Patients Prefer Faster Subcutaneous Administration Of Herceptin® (Trastuzumab) To IV." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/257799.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.